A new approach for treatment of precancerous lesions with curcumin solid–lipid nanoparticle-loaded gels: <i>in vitro</i> and clinical evaluation

Hazzah, Heba A.; Farid, Ragwa M.; Nasra, Maha M A; Zakaria, Mennatallah; Gawish, Yousria; El-Massik, Magda A.; Abdallah, Ossama Y.

doi:10.3109/10717544.2015.1065524

Cited by 35 publications

(30 citation statements)

References 30 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro drug release profile of SA-NPs was investigated via the dialysis method (Hazzah et al, 2016), and DXM was determined using HPLC assay. Phosphate buffer (PBS, pH 7.4) was used as dissolution medium.1 mL DXM-loaded SA-NPs was sealed in a dialysis membrane (MWCO: 3500 Da), and then immersed into 40 mL release medium, free DXM and DXM-loaded NPs (equal DXM) as control.…”

Section: In Vitro Release Of Dxm From Sa-npsmentioning

confidence: 99%

RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

2017

Drug Delivery

View full text Add to dashboard Cite

, and the mechanism is associated with the specific binding between SA and E-selectin receptor expressed on the inflamed vascular endothelial cells. Bio-distribution results further demonstrated the enhanced renal accumulation of DXM is achieved in AKI mice treated with SA-NPs, and its content is 2.70-and 5.88-fold higher than those treated with DXM and NPs at 6 h after intravenous administration, respectively. Pharmacodynamic studies demonstrate SANPs effectively ameliorate renal functions in AKI mice, as reflected by improved blood biochemical indexes, histopathological changes, oxidative stress levels and pro-inflammatory cytokines. Moreover, SA-NPs cause little negative effects on lymphocyte count and bone mineral density while DXM leads to severe osteoporosis. It is concluded that SA-NPs provide an efficient and targeted delivery of DXM for ischemia-reperfusion-induced injury-induced AKI, with improved therapeutic outcomes and reduced adverse effects.ARTICLE HISTORY

show abstract

Section: In Vitro Release Of Dxm From Sa-npsmentioning

confidence: 99%

RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

2017

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…57,58 SLNs have been extensively used in many studies to orally deliver bioactive compounds with an enhanced anticancer effect. 17,57,[59][60][61][62] Genistein is a phytoestrogen that is extensively used for hormone-related cancers, and it has limited bioavailability. Recently, genisteinloaded solid lipid microparticles (SLMs) with a particle size of 6 µm were compared with SLNs with a particle size of about 120 nm in terms of their bioavailability.…”

mentioning

confidence: 99%

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Ganesan

Ramalingam

Karthivashan

et al. 2018

IJN

133

View full text Add to dashboard Cite

Solid lipid nanoparticle (SLN) delivery systems have a wide applicability in the delivery of phyto-bioactive compounds to treat various chronic diseases, including diabetes, cancer, obesity and neurodegenerative diseases. The multiple benefits of SLN delivery include improved stability, smaller particle size, leaching prevention and enhanced lymphatic uptake of the bioactive compounds through oral delivery. However, the burst release makes the SLN delivery systems inadequate for the oral delivery of various phyto-bioactive compounds that can treat such chronic diseases. Recently, the surface-modified SLN (SMSLN) was observed to overcome this limitation for oral delivery of phyto-bioactive compounds, and there is growing evidence of an enhanced uptake of curcumin delivered orally via SMSLNs in the brain. This review focuses on different SLN and SMSLN systems that are useful for oral delivery of phyto-bioactive compounds to treat various chronic diseases.

show abstract

“…The force required to detach the two sided mucosa was recorded. The force (dyne/cm 2 ) needed to break the adhesive bond per unit area was estimated using the following equation (Hazzah et al, 2016):…”

Section: Muccoadhesion Of Ltd-trs-gelmentioning

confidence: 99%

Loratadine bioavailability via buccal transferosomal gel: formulation, statistical optimization,in vitro/in vivocharacterization, and pharmacokinetics in human volunteers

et al. 2017

View full text Add to dashboard Cite

Loratadine (LTD) is an antihistaminic drug that suffers limited solubility, poor oral bioavailability (owing to extensive first-pass metabolism), and highly variable oral absorption. This study was undertaken to develop and statistically optimize transfersomal gel for transbuccal delivery of LTD. Transfersomes bearing LTD were prepared by conventional thin film hydration method and optimized using sequential Quality-by-Design approach that involved Placket-Burman design for screening followed by constrained simplex-centroid design for optimization of a Tween-80/Span-60/Span-80 mixture. The transferosomes were characterized for entrapment efficiency, particle size, and shape. Optimized transferosomes were incorporated in a mucoadhesive gel. The gel was characterized for rheology, ex vivo permeation across chicken pouch buccal mucosa, in vitro release, and mucoadhesion. Pharmacokinetic behavior of LTD formulations was investigated in healthy volunteers following administration of a single 10-mg dose. Optimal transferosomes characterized by submicron size (380 nm), spherical shape and adequate loading capacity (60%) were obtained by using quasi-equal ratio surfactant mixture. In terms of amount permeated, percentage released, and mucoadhesion time, the transferosomal gel proved superior to control, transferosome-free gel. Bioavailability of the transferosomal gel was comparable to Claritin® oral tablets. However, inter-individual variability in C and AUC was reduced by 76 and 90%, respectively, when the buccal gel was used. Linear Correlation of in vitro release with in vivo buccal absorption fractions was established with excellent correlation coefficient (R>0.97). In summary, a novel buccal delivery system for LTD was developed. However, further clinical investigation is warranted to evaluate its therapeutic effectiveness and utility.

show abstract

A new approach for treatment of precancerous lesions with curcumin solid–lipid nanoparticle-loaded gels: in vitro and clinical evaluation

Cited by 35 publications

References 30 publications

RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Loratadine bioavailability via buccal transferosomal gel: formulation, statistical optimization,in vitro/in vivocharacterization, and pharmacokinetics in human volunteers

Contact Info

Product

Resources

About